title: The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy.
abstract: The risk factors and the role of prophylactic antiviral therapy of hepatitis B virus (HBV) reactivation in patients with hepatitis B surface antigen (HBsAg) negative/hepatitis B core antibody (HBcAb) positive disease remain controversial. We reviewed 629 patients with diffuse large B-cell lymphoma (DLBCL). Among 629 patients, 150 of 246 patients with resolved HBV (HBsAg negative and HBcAb positive) were treated with rituximab-combined therapy. Among these 150 patients, none of 104 patients (0.0%) who were hepatitis B surface antibody (HBsAb) positive experienced HBV reactivation versus four of 46 patients (8.7%) who were HBsAb negative (p = 0.008). One of 113 patients (0.9%) with International Prognostic Index (IPI) 0-2 suffered HBV reactivation versus three of the remaining 37 patients (8.1%) with IPI 3-5 (p = 0.047). HBsAb and IPI are potential risk factors for HBV reactivation. The use of prophylactic agents may not be recommended for these patients until the occurrence of HBV reactivation.
authors: Department of Hematology, Institute of Hematology, the First Affiliated Hospital, Zhejiang University College of Medicine , Hangzhou, Zhejiang , China.
authors: Shasha
authors: S
authors: Lu
authors: Yu
authors: Y
authors: Xu
authors: Qitian
authors: Q
authors: Mu
authors: Lihong
authors: L
authors: Cao
authors: Jian
authors: J
authors: Chen
authors: Zhijuan
authors: Z
authors: Zhu
authors: Yinjun
authors: Y
authors: Lou
authors: Haitao
authors: H
authors: Meng
authors: Wenbin
authors: W
authors: Qian
authors: Hongyan
authors: H
authors: Tong
authors: Wenyuan
authors: W
authors: Mai
authors: Jian
authors: J
authors: Huang
authors: Wenjuan
authors: W
authors: Yu
authors: Xiaoying
authors: X
authors: Zhao
authors: Jie
authors: J
authors: Jin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000378:metabolism / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000378:metabolism; D006514:Hepatitis B Surface Antigens / Q000378:metabolism; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment / Q000379:methods / Q000706:statistics & numerical data; D012307:Risk Factors; D000069283:Rituximab / Q000008:administration & dosage; D014758:Viral Core Proteins / Q000378:metabolism; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014758:Viral Core Proteins; D000069283:Rituximab
keywords: Diffuse large B-cell lymphoma; International Prognostic Index; antiviral prophylaxis; hepatitis B virus; reactivation